Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Improvement of Radial Cheek Lines With Hyaluronic Acid–Based Dermal Filler VYC-17.5L

Results of the BEAM Study

Ogilvie, Patricia MD*; Fink, Bernhard PhD; Leys, Christophe MD; Lipko-Godlewska, Sylwia MD, PhD§; Niforos, François MD; Kelly, Regina MA; Kerson, Graeme BSc#; Silberberg, Michael MD, MBA#

doi: 10.1097/DSS.0000000000002057
Original Article: PDF Only
Buy
SDC
PAP

BACKGROUND Radial cheek lines (RCL) may convey an older, potentially less attractive appearance.

OBJECTIVE To evaluate the effectiveness of hyaluronic acid–based dermal filler VYC-17.5L for correcting RCL.

MATERIALS AND METHODS Fifty-three women (40–65 years) received injections of VYC-17.5L in both cheeks on Day 1 (optional Day 14 touch-up). Effectiveness was evaluated on Day 45 by subject-rated dynamic RCL improvement (Global Aesthetic Improvement Scale [GAIS]; primary end point) and independent, noninjecting investigator–rated GAIS; subject Self-Perception of Age (SPA); subject-assessed satisfaction with and natural look of treatment; and instrument-assessed changes in static and dynamic RCL roughness, amplitude, and texture (secondary end points). Safety assessments included injection site responses (ISRs).

RESULTS On Day 45, 98% of subjects rated RCL as improved or much improved (investigator rated: 95%). Subjects with same or older SPA before treatment (n = 38) perceived themselves as 2.0 and 5.5 average years younger after treatment, respectively. Day 45 mean satisfaction with and natural look of treated areas was 7.9/10 and 7.2/10, respectively. Treatment significantly improved RCL roughness, amplitude, and texture (all p < .001). Most common ISRs were hematoma (35.9%), bruising (30.2%), and irregularities/bumps (22.6%); most ISRs were mild.

CONCLUSION VYC-17.5L effectively corrected dynamic RCL, improved instrument-assessed indicators of skin quality, and resulted in younger age perception.

*SkinConcept, Munich, Germany;

University of Goettingen, Goettingen, Germany;

Medical Skincare, Sint-Truiden, Belgium;

§Garden Spa, Krakow, Poland;

Centre Chirurgical Niforos, Lyon, France;

Peloton Advantage, LLC, Parsippany, New Jersey;

#Allergan plc, Marlow, United Kingdom

Address correspondence and reprint requests to: Patricia Ogilvie, MD, SkinConcept, Theatinerstraße 46, Munich 80333, Germany, or e-mail: dr.patricia.ogilvie@skin-concept.de

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the full text and PDF versions of this article on the journal's Web site (www.dermatologicsurgery.org).

This study was sponsored by Allergan plc, Dublin, Ireland. Editorial assistance was provided to the authors by Peloton Advantage, an OPEN Health company, Parsippany, NJ, and was funded by Allergan plc.

P. Ogilvie, B. Fink, C. Leys, S. Lipko-Godlewska, and F. Niforos are investigators for Allergan plc, Marlow, United Kingdom. G. Kerson and M. Silberberg are employees of Allergan plc, Marlow, United Kingdom. R. Kelly provided writing services to the authors, which was funded by Allergan plc.

© 2019 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website